Palifermin biosimilar (Genemen Biotech)

帕利夫明生物类似药 (Genemen Biotech)

Report date: 2022/01/24 09:34:26

Base Information

Drug NamePalifermin biosimilar (Genemen Biotech)

Drug Alias NameLyophilised recombinant human keratinocyte growth factor帕利夫明生物仿制药 (Genemen Biotech)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionFibroblast growth factor receptors agonists

TargetsFibroblast growth factor receptors

Therapy Area/IndicationsStomatitis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenemen Biotech

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGenemen Biotech

Active IndicationsN/A

Inactive IndicationsStomatitis

ATC CodeV03AF08